Angelina Fink
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Angelina Fink has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Kerstin Pfister
Department of Obstetrics and Gynecology, University Hospital Ulm, Ulm, Germany
4 shared publications - Brigitte Rack
Department of Gynecology and Obstetrics, University Hospital Ulm, 89075 Ulm, Germany
3 shared publications - Kristina Veselinovic
Department of Obstetrics and Gynecology, University Hospital Ulm, Ulm, Germany
3 shared publications - Thomas Wolfram Paul Friedl
Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
3 shared publications - Andreas Daniel Hartkopf
Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
2 shared publications - Elena Leinert
Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany
2 shared publications
Latest Publications
- Open Access
- 19 February 2026
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 313 (1) , 102
Age-dependent differences in survival of patients with early breast cancer: analysis of SUCCESS A, B, C trials
Purpose: Elderly breast cancer (BC) patients are commonly at risk of under-treatment, which can negatively affect their prognosis. Therefore, we analyzed age-related survival differences considering clinico-pathological parameters among patients with early BC. Methods: 8190 BC patients from SUCCESS A, B, and C trials who underwent surgery and adjuvant systemic therapy were analyzed. Tumor and nodal stage, grading, biological subtype, types of surgical and systemic therapies, and other clinico-pathological parameters were compared between age groups ≤ 50 years, 51–65 years, > 65 years (chi-square tests). Breast cancer-free interval (BCFI), breast cancer-specific survival (BCSS), overall survival (OS), invasive disease-free survival (iDFS), and distant disease-free survival (DDFS) were analyzed using univariable and adjusted multivariable Cox regression models. Two-way interactions between age and other clinico-pathological parameters were calculated. Results: There were significant differences between the age groups concerning almost all parameters analyzed, especially more advanced tumor stages in the elderly group. Univariable analysis showed significant differences between the age groups for all survival parameters (all p < 0.001). However, after adjustment for other prognostic parameters, an independent significant age effect was found only for iDFS ( p = 0.038), while there was no significant independent age effect on BCFI ( p = 0.286), BCSS ( p = 0.981), OS ( p = 0.131) and DDFS ( p = 0.316). Conclusion: Although elderly BC patients > 65 years had poorer survival, multivariable analysis suggests this difference is mostly attributable to advanced tumor stages rather than age itself. Effective BC screening and research related to the influence of (biological) age on response to cancer therapies could be the next step to improve understanding the relationship between patient age and BC survival.
- 19 February 2026
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 313 (1) , 102
Open AccessAge-dependent differences in survival of patients with early breast cancer: analysis of SUCCESS A, B, C trials
Purpose: Elderly breast cancer (BC) patients are commonly at risk of under-treatment, which can negatively affect their prognosis. Therefore, we analyzed age-related survival differences considering clinico-pathological parameters among patients with early BC. Methods: 8190 BC patients from SUCCESS A, B, and C trials who underwent surgery and adjuvant systemic therapy were analyzed. Tumor and nodal stage, grading, biological subtype, types of surgical and systemic therapies, and other clinico-pathological parameters were compared between age groups ≤ 50 years, 51–65 years, > 65 years (chi-square tests). Breast cancer-free interval (BCFI), breast cancer-specific survival (BCSS), overall survival (OS), invasive disease-free survival (iDFS), and distant disease-free survival (DDFS) were analyzed using univariable and adjusted multivariable Cox regression models. Two-way interactions between age and other clinico-pathological parameters were calculated. Results: There were significant differences between the age groups concerning almost all parameters analyzed, especially more advanced tumor stages in the elderly group. Univariable analysis showed significant differences between the age groups for all survival parameters (all p < 0.001). However, after adjustment for other prognostic parameters, an independent significant age effect was found only for iDFS ( p = 0.038), while there was no significant independent age effect on BCFI ( p = 0.286), BCSS ( p = 0.981), OS ( p = 0.131) and DDFS ( p = 0.316). Conclusion: Although elderly BC patients > 65 years had poorer survival, multivariable analysis suggests this difference is mostly attributable to advanced tumor stages rather than age itself. Effective BC screening and research related to the influence of (biological) age on response to cancer therapies could be the next step to improve understanding the relationship between patient age and BC survival.
- Open Access
- 9 September 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0331203
The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors
Background: Current aftercare in breast cancer survivors aims to detect local recurrences or contralateral disease, while the detection of distant metastases has not been a central focus due to a lack of evidence supporting an effect on overall survival. However, the data underpinning these guidelines are mainly from trials of the 1980s/1990s and have not been updated to reflect the significant advancements in diagnostic and therapeutic options that have emerged over the past 40 years. In this trial, the aim is to test whether a liquid biopsy-based detection of (oligo-) metastatic disease at an early pre-symptomatic stage followed by timely treatment can impact overall survival compared to current standard aftercare. Methods: In this partially double-blinded superiority study, intensified liquid biopsy-guided surveillance will be assessed versus standard surveillance in medium-to-high-risk early breast cancer patients. Intensive surveillance comprises 3-monthly tests of circulating free tumor DNA (ctDNA), circulating tumor cells (CTC) and serum tumor markers CEA, CA 27.29 and CA125. Upon positivity of biomarker and/or symptoms, staging examinations are initiated. In total, 3500 patients will be randomized in a 1:1 ratio after completion of primary antineoplastic therapy. Co-primary endpoints are overall survival (OS) and the overall lead time effect. The trial will be accompanied by an extensive translational research program. Discussion: A risk-based aftercare and regular screening for asymptomatic metastatic disease with molecular markers in the absence of any radiological findings can potentially revolutionize current follow-up care of breast cancer survivors and enable potential treatment even before patients suffer from symptomatic, incurable disease.
- 9 September 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0331203
Open AccessThe SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors
Background: Current aftercare in breast cancer survivors aims to detect local recurrences or contralateral disease, while the detection of distant metastases has not been a central focus due to a lack of evidence supporting an effect on overall survival. However, the data underpinning these guidelines are mainly from trials of the 1980s/1990s and have not been updated to reflect the significant advancements in diagnostic and therapeutic options that have emerged over the past 40 years. In this trial, the aim is to test whether a liquid biopsy-based detection of (oligo-) metastatic disease at an early pre-symptomatic stage followed by timely treatment can impact overall survival compared to current standard aftercare. Methods: In this partially double-blinded superiority study, intensified liquid biopsy-guided surveillance will be assessed versus standard surveillance in medium-to-high-risk early breast cancer patients. Intensive surveillance comprises 3-monthly tests of circulating free tumor DNA (ctDNA), circulating tumor cells (CTC) and serum tumor markers CEA, CA 27.29 and CA125. Upon positivity of biomarker and/or symptoms, staging examinations are initiated. In total, 3500 patients will be randomized in a 1:1 ratio after completion of primary antineoplastic therapy. Co-primary endpoints are overall survival (OS) and the overall lead time effect. The trial will be accompanied by an extensive translational research program. Discussion: A risk-based aftercare and regular screening for asymptomatic metastatic disease with molecular markers in the absence of any radiological findings can potentially revolutionize current follow-up care of breast cancer survivors and enable potential treatment even before patients suffer from symptomatic, incurable disease.
- Open Access
- 1 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8498
Is Radiographic Aftercare Obsolete? How Testing Positive for ctDNA Can Be a Precedent for Late Relapse, Even in Low-Risk Hormone-Receptor-Positive Breast Cancer
Current aftercare after early breast cancer overlooks recent evidence on circulating free tumor DNA (ctDNA). In this case report, we present a patient with low-risk hormone-receptor-positive breast cancer. ctDNA was first detected using a tumor-informed approach 12 months after the initial diagnosis and remained positive throughout adjuvant therapy with letrozole, while routine staging examinations showed no signs of relapse. Clinical relapse was ultimately identified nearly six years after the initial diagnosis, resulting in a lead time of four years and nine months. Current studies on ctDNA in the adjuvant setting have been conducted in high-risk cohorts and have shown a median molecular lead time of 8.9–12.4 months. Our study supports the need for large randomized clinical trials involving low-risk breast cancer patients to drive changes in clinical practice.
- 1 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8498
Open AccessIs Radiographic Aftercare Obsolete? How Testing Positive for ctDNA Can Be a Precedent for Late Relapse, Even in Low-Risk Hormone-Receptor-Positive Breast Cancer
Current aftercare after early breast cancer overlooks recent evidence on circulating free tumor DNA (ctDNA). In this case report, we present a patient with low-risk hormone-receptor-positive breast cancer. ctDNA was first detected using a tumor-informed approach 12 months after the initial diagnosis and remained positive throughout adjuvant therapy with letrozole, while routine staging examinations showed no signs of relapse. Clinical relapse was ultimately identified nearly six years after the initial diagnosis, resulting in a lead time of four years and nine months. Current studies on ctDNA in the adjuvant setting have been conducted in high-risk cohorts and have shown a median molecular lead time of 8.9–12.4 months. Our study supports the need for large randomized clinical trials involving low-risk breast cancer patients to drive changes in clinical practice.
- Open Access
- 15 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (22) , 16366
The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers
The NATALEE study showed a significant benefit in invasive disease-free survival (iDFS) for patients with HR+/HER2− early breast cancer (eBC) at intermediate and high risk of recurrence who were treated with the CDK4/6 inhibitor Ribociclib in combination with endocrine therapy (ET). This retrospective study aims to apply the NATALEE inclusion criteria to a representative real-world cohort to estimate the proportion of HR+/HER2− breast cancer patients eligible for adjuvant Ribociclib therapy. Patients who underwent full surgical treatment for eBC between January 2018 and December 2020 at two large German university breast cancer centers (University of Ulm, University of Tuebingen) were included. Descriptive statistics were used to characterize the patient population eligible for Ribociclib treatment based on the NATALEE study’s inclusion criteria. Out of 2384 enrolled patients, 1738 had HR+/HER2− eBC, of whom 43% (747/1738) met the NATALEE inclusion criteria. Of note, these patients were older, received less chemotherapy and presented with less advanced tumor stages compared to the NATALEE study cohort. Additionally, compared to the NATALEE study cohort, fewer patients had lymph node involvement (72.4% vs. 88.7%). Our analysis suggests that approximately 43% of all HR+/HER2− breast cancer patients will qualify for Ribociclib treatment. Given the numerous treatment options for patients with HR+/HER2− eBC, as well as the differences between the NATALEE cohort and patients in the real-world clinical setting, future analyses will be needed to determine which patients would benefit most from adjuvant CDK4/6 inhibitor treatment.
- 15 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (22) , 16366
Open AccessThe Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers
The NATALEE study showed a significant benefit in invasive disease-free survival (iDFS) for patients with HR+/HER2− early breast cancer (eBC) at intermediate and high risk of recurrence who were treated with the CDK4/6 inhibitor Ribociclib in combination with endocrine therapy (ET). This retrospective study aims to apply the NATALEE inclusion criteria to a representative real-world cohort to estimate the proportion of HR+/HER2− breast cancer patients eligible for adjuvant Ribociclib therapy. Patients who underwent full surgical treatment for eBC between January 2018 and December 2020 at two large German university breast cancer centers (University of Ulm, University of Tuebingen) were included. Descriptive statistics were used to characterize the patient population eligible for Ribociclib treatment based on the NATALEE study’s inclusion criteria. Out of 2384 enrolled patients, 1738 had HR+/HER2− eBC, of whom 43% (747/1738) met the NATALEE inclusion criteria. Of note, these patients were older, received less chemotherapy and presented with less advanced tumor stages compared to the NATALEE study cohort. Additionally, compared to the NATALEE study cohort, fewer patients had lymph node involvement (72.4% vs. 88.7%). Our analysis suggests that approximately 43% of all HR+/HER2− breast cancer patients will qualify for Ribociclib treatment. Given the numerous treatment options for patients with HR+/HER2− eBC, as well as the differences between the NATALEE cohort and patients in the real-world clinical setting, future analyses will be needed to determine which patients would benefit most from adjuvant CDK4/6 inhibitor treatment.
- 1 September 2021
- Published by Springer Nature in Gynäkologische Endokrinologie
- Vol. 19 (3) , 249-251
Hypercalcemic ovarian cancer in a 12-year-old girl
- 1 September 2021
- Published by Springer Nature in Gynäkologische Endokrinologie
- Vol. 19 (3) , 249-251
Hypercalcemic ovarian cancer in a 12-year-old girl
- 4 May 2021
- Published by Springer Nature in Der Onkologe
- Vol. 27 (7) , 697-702
Entwicklungen in der medikamentösen Therapie des triple-negativen Mammakarzinoms
- 4 May 2021
- Published by Springer Nature in Der Onkologe
- Vol. 27 (7) , 697-702
Entwicklungen in der medikamentösen Therapie des triple-negativen Mammakarzinoms